Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Change in Accured Expenses (2017 - 2023)

Historic Change in Accured Expenses for Dianthus Therapeutics (DNTH) over the last 6 years, with Q2 2023 value amounting to -$1.7 million.

  • Dianthus Therapeutics' Change in Accured Expenses fell 16982.34% to -$1.7 million in Q2 2023 from the same period last year, while for Jun 2023 it was -$2.6 million, marking a year-over-year decrease of 70914.83%. This contributed to the annual value of $973000.0 for FY2022, which is 53594.77% up from last year.
  • Per Dianthus Therapeutics' latest filing, its Change in Accured Expenses stood at -$1.7 million for Q2 2023, which was down 16982.34% from -$3.3 million recorded in Q1 2023.
  • In the past 5 years, Dianthus Therapeutics' Change in Accured Expenses registered a high of $3.7 million during Q4 2019, and its lowest value of -$3.3 million during Q1 2023.
  • In the last 4 years, Dianthus Therapeutics' Change in Accured Expenses had a median value of -$623000.0 in 2022 and averaged -$136818.2.
  • In the last 5 years, Dianthus Therapeutics' Change in Accured Expenses skyrocketed by 64388.78% in 2019 and then plummeted by 28870.78% in 2023.
  • Over the past 4 years, Dianthus Therapeutics' Change in Accured Expenses (Quarter) stood at $3.7 million in 2019, then tumbled by 168.62% to -$2.5 million in 2020, then surged by 159.64% to $1.5 million in 2022, then crashed by 210.66% to -$1.7 million in 2023.
  • Its last three reported values are -$1.7 million in Q2 2023, -$3.3 million for Q1 2023, and $1.5 million during Q4 2022.